Impact of the relative dose intensity on survival of patients with high‐risk myelodysplastic syndromes treated with Azacitidine

We performed a retrospective analysis of 93 myelodysplastic syndromes (MDS) patients with intermediate 2 or high‐risk IPSS score to study the impact of Azacitidine (AZA) relative dose intensity (RDI) <80% on the overall survival (OS). There were 51.6% of patients who had full dose and 48.4% had d...

Descripción completa

Detalles Bibliográficos
Autores principales: Laribi, Kamel, Bolle, Delphine, Alani, Mustafa, Ghnaya, Habib, Besançon, Anne, Farhi, Jonathan, Mheidly, Kayane, Denizon, Nathalie, Baugier de Materre, Alix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536936/
https://www.ncbi.nlm.nih.gov/pubmed/30993891
http://dx.doi.org/10.1002/cam4.2121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536936/
https://www.ncbi.nlm.nih.gov/pubmed/30993891
http://dx.doi.org/10.1002/cam4.2121

Ejemplares similares